ASCO 2021: Allogene announces the latest clinical data of two allogeneic CD19 CAR-T drug treatments

Recent popular reports from Yimaike ★Iterative update of antibody drugs, how to improve drug characterization and quality controlMedical Class ★The U.
S.
FDA grants Janssen BCMA/CD dual-antibody breakthrough therapy designationYikeman broke the news on June 8, 2021 / Yimaike News eMedClub News/--Recently, at the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Allogene Therapeutics presented the CD19 monoclonal antibody allogeneic CAR-T drugs (ALLO-501 and ALLO-501A) in the form of two sets of posters.
) Mainly, data from multiple studies on the treatment of relapsed/refractory non-Hodgkin’s lymphoma (R/R NHL)
.

 Allogeneic, also known as "off-the-shelf" or universal, is designed to express CAR by collecting T cells from healthy donors to identify and destroy cancer cells and limit the patient's own Immune response
.

They can be used directly and do not need to be tailored for each patient
.

The use of universal CAR-T cell therapy may simplify cell manufacturing engineering and may even allow the creation of "off-the-shelf" products, facilitating faster and cheaper treatments
.

Allogene Therapeutics is a clinical-stage biotechnology company that is at the leading level in the field of cancer allogeneic CAR-T (AlloCAR T) therapy
.

The company uses the allogeneic CAR-T technology platform based on the gene editing technology TALEN® developed by Cellectis, and cooperates with Servier to jointly develop drugs
.

Its goal is to provide ready-made cell therapy to more patients on-demand, more reliable, and on a larger scale
.

 Recommended article: GM CAR-T boss Cellectis once again expands its exclusive global license, the field is hot at home and abroadYimai's new observation ALPHA (NCT03939026) study is to evaluate ALLO-501 in the treatment of R/R large B cell lymphoma (LBCL) ) Or a phase 1 study in adult patients with follicular lymphoma (FL)
.

The main research objectives are the safety and dose-limiting toxicity (DLT) of ALLO-647/fludarabine (Flu)/cyclophosphamide (Cy) before the use of ALLO-501
.

98% of the enrolled patients received ALLO-501 treatment, and the median time from enrollment to start of treatment was 5 days
.

The ALPHA2 (NCT04416984) study is a phase 1/2 study evaluating ALLO-501A in the treatment of adult patients with R/R LBCL
.

ALPHA2 is a single-group, open-label Phase 1/2 study that determines the dose of ALLO-501A and a lymphatic removal plan based on ALLO-647 on the basis of the ALPHA trial
.

The UNIVERSAL (NCT04093596) study is a phase 1 study evaluating ALLO-715 in the treatment of adult patients with R/R MM
.

ALLO-715 is a CAR-T cell therapy for relapsed/refractory (R/R) multiple myeloma (MM)
.

The data disclosed this time is the data from the first human test of ALLO-501A
.

Combining the data of ALPHA and ALPHA2, ALLO-501 and ALLO-501A (one or two doses) can tolerate the combination of ALLO-647 lymphocyte removal well
.

If there is new evidence of meaningful clinical benefit, re-administration of AlloCAR-T can be considered in the advanced stage or early consolidation of the disease
.

 Scan the QR code and read the detailed data reference materials of this article: 1.
https:// allo-501a-in-relapsed-refractory-non-hodgkin-lymphoma-at-the-2021-annual-meeting-of-the-american-society-of-clinical-oncology/medicine has always been committed to the forefront of bio-innovative drugs Original news reports on technology, industry trends, industry insights, etc.
, all-media high-end matrix users reached 160,000+, of which industrial users accounted for more than 50%, scientific research and clinical users accounted for about 30%, and investment institution users exceeded 5%
.

In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups
.